Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
63.32 USD | -1.52% | +4.14% | +58.64% |
05-13 | RxSight Raises $115 Million From Public Offering of Shares | MT |
05-07 | Wells Fargo Adjusts RxSight Price Target to $68 From $61, Maintains Overweight Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+58.64% | 2.51B | D | ||
-5.09% | 182B | C+ | ||
+3.05% | 112B | C | ||
-2.85% | 68.58B | A | ||
+4.37% | 51.58B | B- | ||
+8.55% | 44.24B | B- | ||
+9.45% | 43.65B | B+ | ||
+24.49% | 32.46B | B | ||
+20.94% | 25.99B | A- | ||
+0.35% | 25.61B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RXST Stock
- Ratings RxSight, Inc.